She and her colleagues illustrated the role of direct immunofluorescence plays in the evaluation of autoimmune blistering disorders.
At the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana, Alina Bridges, DO, FAAD and Director of Dermapathology at the Zucker School of Medicine at Hofstra/Northwell presented during the session “A Practical Approach to Direct Immunofluorescence.” As she and her colleagues explored challenging cases to show the role immunofluorescence plays, the limitations, and best practices to maximize the yield, Bridges focused on the benefits and challenges of them in the treatment of pemphigus and pemphigoid disorders.She shared the biggest takeaways from her role in the session focused on evaluating and treating autoimmune blistering conditions with Dermatology Times®.
Along with this session, she is also taking part in two upcoming sessions:
Clinicopathologic Self-assessment - Saturday, March 18| 1:00 PM - 4:00 PM
Making the Most of Your Time: Optimizing Productivity in 2023 - Sunday, March 19| 3:30 pm to 5:30 pm
Alina Bridges, DO, FAAD: I am Dr. Alina Bridges, and I am the Chief of Dermapathology at the Zucker School of Medicine at Hofstra/Northwell in New York.
Dermatology Times: What is the importance of immunofluorescence in pemphigus and pemphigoid disorders?
Bridges: You pretty much cannot diagnose those diseases without using immunofluorescence because the clinical findings can sometimes be notvery specific and the histopathology can overlap with other conditions. So, you have to use direct immunofluorescence and even serum-based studies to arrive at the final diagnosis in these cases. And then there's pitfalls that can occur, because patients are because clinicians often forget to they don't know where to sample from in these conditions. So, we're always getting inadequate specimens and they might not be put into the right collection media have for us to do that test correctly.
Dermatology Times: What challenges do pemphigus and pemphigoid disorders bring?
Bridges: They can be challenging diseases because they also now have there's associations with different medications and underlying systemic disorders that can occur in these patients and these diseases can occur in both young and older patients.
Transcript edited for clarity.
Alina Bridges, DO has no financial disclosures.